Patents by Inventor Tyler STARR

Tyler STARR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE CORONAVIRUS PROTEINS AND VACCINE COMPOSITIONS THEREOF
    Publication number: 20250002907
    Abstract: Provided herein are compositions and methods comprising mutated coronavirus “S” spike proteins or receptor binding domains thereof that have an increased expression level, yield and stability compared to its corresponding native or wild-type coronavirus spike protein under the same expression, culture or storage conditions. These mutated spike proteins can be used for generating a protein-based vaccine against one or more coronaviruses.
    Type: Application
    Filed: September 13, 2024
    Publication date: January 2, 2025
    Inventors: Daniel ELLIS, Neil KING, Jesse BLOOM, Tyler STARR, Allison GREANEY
  • Stable coronavirus proteins and vaccine compositions thereof
    Patent number: 12129465
    Abstract: Provided herein are compositions and methods comprising mutated coronavirus “S” spike proteins or receptor binding domains thereof that have an increased expression level, yield and stability compared to its corresponding native or wild-type coronavirus spike protein under the same expression, culture or storage conditions. These mutated spike proteins can be used for generating a protein-based vaccine against one or more coronaviruses.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: October 29, 2024
    Assignees: UNIVERSITY OF WASHINGTON, FRED HUTCHINSON RESEARCH CENTER
    Inventors: Daniel Ellis, Neil King, Jesse Bloom, Tyler Starr, Allison Greaney
  • STABLE CORONAVIRUS PROTEINS AND VACCINE COMPOSITIONS THEREOF
    Publication number: 20220325279
    Abstract: Provided herein are compositions and methods comprising mutated coronavirus “S” spike proteins or receptor binding domains thereof that have an increased expression level, yield and stability compared to its corresponding native or wild-type coronavirus spike protein under the same expression, culture or storage conditions. These mutated spike proteins can be used for generating a protein-based vaccine against one or more coronaviruses.
    Type: Application
    Filed: December 28, 2021
    Publication date: October 13, 2022
    Applicants: UNIVERSITY OF WASHINGTON, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Daniel ELLIS, Neil KING, Jesse BLOOM, Tyler STARR, Allison GREANEY